Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AccuLNP CRISPR formulation is a lipid nanoparticle (LNP) based delivery system designed for the efficient transfection of nucleic acids, including messenger RNA (mRNA) and CRISPR/Cas9 ribonucleoproteins (RNPs), into cells. It utilizes advanced LNP technology to encapsulate these genetic components, facilitating their entry into target cells for various applications such as gene editing and the development of novel mRNA therapies. The formulation is available in versions optimized for both in vitro and in vivo use, demonstrating high transfection efficiency and low cytotoxicity across diverse cell lines. It acts as a crucial vehicle for enabling CRISPR/Cas9-mediated gene editing by delivering the Cas9 nuclease and guide RNA complex, which then precisely targets and cleaves specific DNA sequences, allowing for gene knock-out, knock-in, or correction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AccuLNP CRISPR formulation.